HDA2 Inhibitors
The chemicals designed to inhibit HDA2 operate mainly by interfering with the catalytic domain responsible for its deacetylase activity. For instance, Trichostatin A and Vorinostat are both HDAC inhibitors that act on Class I and II HDACs, effectively blocking HDA2's capacity to remove acetyl groups from histone and non-histone proteins. This disruption leads to an increase in acetylated histones, thereby affecting the regulatory roles HDA2 plays in gene expression. Sodium Butyrate, a short-chain fatty acid, also blocks deacetylation activity of Class I and II HDACs including HDA2, causing a decrease in gene silencing mediated by this protein. Similarly, Mocetinostat and Apicidin are isotype-selective and Class I HDAC inhibitors, respectively, that impede HDA2's enzymatic domain, leading to altered epigenetic regulation.
On the other hand, Panobinostat and Belinostat are pan-HDAC inhibitors that broadly disrupt the enzymatic activities of multiple HDACs, including HDA2. Their inhibition increases acetylation of histones, which in turn alters gene expression profiles. Specificity towards Class I HDACs is a characteristic of Entinostat and Romidepsin, both of which directly affect HDA2's deacetylation function, causing increased acetylation and consequent disruption in gene regulation. Second-generation HDAC inhibitors like JNJ-26481585 are designed to target multiple HDACs while maintaining higher potencies. In the case of HDA2, this leads to altered gene repression typically mediated by this protein. Tubastatin A, although less potent on HDA2, can still affect it through cross-reaction, disrupting its role in gene regulation by increasing acetylation levels.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor that interferes directly with the catalytic domain of HDA2, blocking its ability to deacetylate histones and thereby altering gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor targeting Class I and II HDACs, including HDA2. Inhibits the removal of acetyl groups from histone and non-histone proteins, affecting HDA2-mediated repression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Short-chain fatty acid that inhibits Class I and II HDACs like HDA2. Blocks deacetylation activity, leading to increased acetylation of histones and a corresponding decrease in HDA2-mediated gene silencing. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
Isotype-selective HDAC inhibitor that preferentially inhibits Class I HDACs. Impedes HDA2 by blocking its catalytic domain, leading to increased histone acetylation. | ||||||
Apicidin | 183506-66-3 | sc-202061 sc-202061A | 1 mg 5 mg | $108.00 $336.00 | 9 | |
HDAC inhibitor affecting Class I HDACs. It blocks the enzymatic domain of HDA2, leading to increased levels of acetylated histones, thereby affecting the epigenetic regulation. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
Class I-specific HDAC inhibitor, directly affecting HDA2's deacetylation function. Causes increased acetylation and consequent disruption in gene regulation. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
Pan-HDAC inhibitor affecting multiple HDACs including HDA2. Disrupts HDA2's ability to deacetylate histones, leading to altered gene expression profiles. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
Pan-HDAC inhibitor, effectively blocking the catalytic activities of HDA2 among other HDACs. Leads to increased acetylation of histones, affecting the regulatory roles of HDA2. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
Second-generation HDAC inhibitor targeting multiple HDACs, including HDA2. Its mechanism involves direct inhibition of the catalytic domain, altering the gene repression typically mediated by HDA2. | ||||||
ITF2357 | 732302-99-7 | sc-364513 sc-364513A | 5 mg 50 mg | $340.00 $1950.00 | ||
Broad-spectrum HDAC inhibitor affecting HDA2 by disrupting its catalytic domain. Causes changes in the epigenetic landscape by inhibiting deacetylation activity. | ||||||